Core Viewpoint - 微泰医疗-B (02235.HK) announced a share buyback of 39,000 shares at a cost of HKD 260,000 on November 24 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 260,000 [1] - The number of shares repurchased was 39,000 [1]

Group 1 - The company, 微泰医疗-B (02235), announced a share buyback on November 24, 2025, spending HKD 261,900 to repurchase 38,600 shares [1] - The buyback price ranged from HKD 6.52 to HKD 6.88 per share [1]

Core Viewpoint - MicroTech Medical-B (02235) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 38,600 shares at a total cost of HKD 261,900 [1] - The buyback price ranges from HKD 6.52 to HKD 6.88 per share [1] - The buyback is scheduled for November 24, 2025 [1]

| 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年11月21日 | | 166,470,242 | 2,705,600 | | 169,175,842 | | 1). 購回股份 (股份被持作庫存股份) | | | -38,600 0.0232 % | 38,600 HKD | 6.7842 | | | 變動日期 | 2025年11月24日 | | | | | | | 於下列日期結 ...

Core Viewpoint - The chairman of MicroTech Medical (02235.HK), Zheng Pan, has reduced his stake by selling 2.09 million shares at a price of HKD 6.9 per share, totaling HKD 14.42 million, resulting in a new holding of approximately 38.70 million shares, representing 22.88% of the company [1][1][1]. Group 1: Shareholder Activity - Zheng Pan sold 2.09 million shares of MicroTech Medical at HKD 6.9 each, amounting to HKD 14.42 million [1][1][1]. - After the sale, his remaining shares are approximately 38.70 million, which is 22.88% of the total shares [1][1][1]. Group 2: Stock Performance - As of November 24, 2025, MicroTech Medical-B closed at HKD 6.8, unchanged from the previous trading day, with a trading volume of 79,500 shares and a turnover of HKD 532,700 [1][1][1]. - The stock has received a "Buy" rating from one investment bank in the last 90 days [1][1][1]. Group 3: Company Metrics - MicroTech Medical-B has a market capitalization of HKD 1.132 billion, ranking 21st in the medical device II industry [1][1][1]. - Key performance indicators include: - ROE: -1.36% (industry average: -4.03%, rank: 20) [1][1][1] - Market capitalization: HKD 1.132 billion (industry average: HKD 4.94 billion, rank: 21) [1][1][1] - Revenue: HKD 441 million (industry average: HKD 1.195 billion, rank: 18) [1][1][1] - Net profit margin: -0.93% (industry average: -16.5%, rank: 18) [1][1][1] - Gross profit margin: 51.66% (industry average: 54.89%, rank: 18) [1][1][1] - Debt ratio: 10.8% (industry average: 29.03%, rank: 5) [1][1][1].

Group 1 - The chairman of the board, Zheng Pan, reduced his stake in Weitai Medical (02235) by 2.09 million shares at a price of HKD 6.9 per share, totaling HKD 14.421 million [1] - After the reduction, the latest number of shares held by Zheng Pan is approximately 38.707 million, representing a holding percentage of 22.88% [1]

Group 1 - The chairman of the board, Zheng Pan, reduced his stake in Weitai Medical (02235) by selling 2.09 million shares at a price of HKD 6.9 per share, totaling HKD 14.421 million [1] - After the reduction, the latest number of shares held by Zheng Pan is approximately 38.7007 million, representing a holding percentage of 22.88% [1]

Summary of Weitai Medical Conference Call Company Overview - **Company**: Weitai Medical - **Industry**: Continuous Glucose Monitoring (CGM) Devices Key Points Industry and Market Performance - Weitai Medical's CGM device shipments and user numbers have increased significantly, with shipments up over 600% and user numbers up nearly 300% year-on-year, ranking first in the CGM category on Tmall [2][3] - The international business growth rate is significantly higher than the company's average, particularly in emerging markets such as Asia-Pacific, Latin America, and Africa, with market share and brand influence improving through participation in large tenders and the establishment of medical insurance service systems [2][4] Financial Performance and Projections - The company achieved a revenue growth target of at least 40% for 2025, with CGM category growth expected to be double that of the overall company growth [5] - The CGM gross margin remains stable, with cost reductions of approximately 10-20% achieved through supply chain optimization and automated production lines [2][11] - The company anticipates clear profit growth in 2026, following its first profitable year in 2025 [5][21] Patent Litigation and Strategy - Weitai Medical is actively responding to Abbott's patent litigation, asserting that the validity of the disputed 072 patent is unstable and preparing new design strategies to circumvent potential risks [2][6] - The impact of the patent dispute on the European market is limited, as sales in that region account for less than 5% of international CGM sales [6][7] Product Development and Innovation - The company plans to enhance investment in overseas markets, clinical support personnel, and backend R&D, particularly in core positions related to structure, software, and algorithms [5] - New product designs, including a next-generation split CGM, are set to optimize the product portfolio [5][12] Sales and Marketing Strategy - Weitai Medical's pricing strategy positions its CGM products 20-30% lower than Abbott's, while maintaining a similar gross margin [2][12] - The company has seen significant online sales growth, particularly on platforms like Tmall and Xiaohongshu, with a focus on enhancing brand competitiveness through targeted marketing strategies [17] Challenges and Competitive Landscape - The competitive landscape in regions like Latin America and Southeast Asia is relatively less intense, with fewer competitors compared to the domestic market [10] - The company is prepared for potential challenges in the European market, including software and compound-related disputes, and has strategies in place to address these risks [7][10] Future Outlook - Weitai Medical's core products focus on CGM and closed-loop insulin pump systems, with expectations for significant contributions to revenue growth from these innovations [19] - The company aims to establish a stronger product portfolio targeting both domestic and international markets, with a focus on cost reduction and technological advancements [20] Miscellaneous - The recent share sale by the actual controller was due to tax considerations, not a personal reduction in holdings [2][8] - The company does not anticipate needing to undergo new clinical approval processes for product design changes, as these do not involve material changes [16] This summary encapsulates the key insights from Weitai Medical's conference call, highlighting the company's strong market performance, strategic initiatives, and future growth prospects.

Core Viewpoint - 微泰医疗-B (02235.HK) announced a share buyback of 52,000 shares at a cost of HKD 354,000 on November 21 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 354,000 [1] - The number of shares repurchased was 52,000 [1]

Group 1 - The company, MicroTech Medical-B (02235), announced a share buyback plan [1] - The company plans to repurchase approximately 52,000 shares at a cost of about HKD 354,100 [1] - The buyback is scheduled for November 21, 2025 [1]